Abstract: Apparatuses, systems, and techniques to process image frames. In at least one embodiment, one or more intermediate video frames are generated between a first video frame and a second video frame. In at least one embodiment, the one or more intermediate video frames are generated based, at least in part, on depth information of one or more pixels of the first video frame or second video frame.

Abstract: The present aspects include a magnetic detacher including a housing having a wall that defines a nest configured to receive a security tag; a gate member and an actuator configured to move the gate member between a closed position and an open position, wherein the gate member in the closed position blocks the nest, and in the open position allows access to the nest; a magnet positioned on an opposite side of the housing relative to the nest and adjacent to the nest, the magnet having a field in an area of the nest sufficient to unlock a magnetic lock of the security tag; and a processor in communication with the actuator and with a transaction system, wherein the processor is configured to control the actuator to move the gate member from the closed position to the open position based on receipt of an unlock signal from the transaction system.

Abstract: The present disclosure relates to novel pan-KRAS glutarimide-containing compounds with KRAS degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment diseases and conditions.

Abstract: Systems and methods described herein include implementation of road surface-based localization techniques for advanced vehicle features and control methods including advanced driver assistance systems (ADAS), lane drift detection, passing guidance, bandwidth conservation and caching based on road data, vehicle speed correction, suspension and vehicle system performance tracking and control, road estimation calibration, and others.

Abstract: The present disclosure relates to novel pan-KRAS glutarimide-containing compounds with KRAS degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment diseases and conditions.

Abstract: The present disclosure relates to at least one entity chosen from a compound of Formula (I), tautomers, stereoisomers or a mixture of stereoisomers, hydrates, and deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, and their use as epidermal growth factor receptor (EGFR) degraders for the prevention and treatment of diseases and conditions, e.g., cancer. The present disclosure also relates to pharmaceutical compositions containing such entities, and their use in treating or preventing a disease or disorder associated with EGFR.

Abstract: The present disclosure relates to novel glutarimide-containing compounds with KRAS mutant form degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of diseases and conditions.

Abstract: The disclosure provides quinazoline based compounds and pharmaceutical compositions thereof, which are useful for inhibiting EGFR, as well as methods for using such compounds to treat cancer associated with an EGFR or HER2 exon 20 insertion mutation.

Abstract: The present disclosure relates to novel pan-KRAS glutarimide-containing compounds with KRAS degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment diseases and conditions.

Abstract: The present disclosure relates to novel pan-KRAS glutarimide-containing compounds with KRAS degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment diseases and conditions.

Abstract: The present disclosure relates to novel pan-KRAS glutarimide-containing compounds with KRAS degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment diseases and conditions.

Abstract: The present disclosure relates to novel glutarimide-containing compounds with KRAS mutant form degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of diseases and conditions.

Abstract: The present disclosure relates to novel compounds that degrade Bruton's tyrosine kinase (BTK), pharmaceutical compositions containing such compounds, and their use in prevention and treatment of conditions modulated by BTK.

Abstract: The disclosure provides sulfonamides based compounds and pharmaceutical compositions thereof, which are useful for inhibiting one or more mutations of EGFR, as well as methods for using such compounds to treat cancer associated with EGFR mutations.

Abstract: The present disclosure relates to novel compounds of Formula (I) that degrade Bruton's tyrosine kinase (BTK), pharmaceutical compositions containing such compounds, and their use in prevention and treatment of conditions modulated by BTK.

Abstract: The present disclosure relates to novel compounds that degrade Bruton's tyrosine kinase (BTK), pharmaceutical compositions containing such compounds, and their use in prevention and treatment of conditions modulated by BTK.

Abstract: An embodiment of the present application provides a temperature adaptive control circuit for a light emitting diode and a lighting and/or signaling apparatus. The control circuit includes: a light emitting diode load circuit unit in which one or more light emitting diodes are connected; and a temperature adaptive circuit unit comprising a positive temperature coefficient thermistor and a negative temperature coefficient thermistor connected in series, wherein the temperature adaptive circuit unit is configured such that current flowing through the one or more light emitting diodes in the light emitting diode load circuit unit is a function of sum of resistance of the positive temperature coefficient thermistor and resistance of the negative temperature coefficient thermistor. It not only can compensate the variation of the luminescent intensity with the temperature in a desired working temperature for the LEDs, but also can achieve overheating protection for the LEDs to avoid damage thereof.

Abstract: The present invention provides edible compositions comprising a sweet taste modulator or bitter taste blocker of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of sugar in a food product, methods of reducing the caloric intake in a diet, and methods of enhancing sweet taste or blocking a bitter taste in a food product.

Abstract: An embodiment of the present application provides a temperature adaptive control circuit for a light emitting diode and a lighting and/or signaling apparatus. The control circuit includes: a light emitting diode load circuit unit in which one or more light emitting diodes are connected; and a temperature adaptive circuit unit comprising a positive temperature coefficient thermistor and a negative temperature coefficient thermistor connected in series, wherein the temperature adaptive circuit unit is configured such that current flowing through the one or more light emitting diodes in the light emitting diode load circuit unit is a function of sum of resistance of the positive temperature coefficient thermistor and resistance of the negative temperature coefficient thermistor. It not only can compensate the variation of the luminescent intensity with the temperature in a desired working temperature for the LEDs, but also can achieve overheating protection for the LEDs to avoid damage thereof.

Abstract: Compounds of formula (I) including pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.